Financial reports
Current reports
6-K
Report of Foreign Private Issuer
10 Jun 24
6-K
YS Biopharma Announces Name Change to LakeShore Biopharma
24 May 24
6-K
YS Biopharma Announces Results of Extraordinary General Meeting
21 May 24
6-K
Report of Foreign Private Issuer
7 May 24
6-K
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
29 Apr 24
6-K
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
19 Apr 24
6-K
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
18 Apr 24
6-K
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
9 Apr 24
6-K
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
3 Apr 24
6-K
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
5 Mar 24
Registration and prospectus
S-8
Registration of securities for employees
20 May 24
424B3
Prospectus supplement
8 May 24
POS AM
Prospectus update (post-effective amendment)
23 Jan 24
424B3
Prospectus supplement
31 Oct 23
424B3
Prospectus supplement
26 Sep 23
424B3
Prospectus supplement
25 Sep 23
424B3
Prospectus supplement
25 Sep 23
424B3
Prospectus supplement
15 Aug 23
POS AM
Prospectus update (post-effective amendment)
8 Aug 23
S-8
Registration of securities for employees
7 Jul 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
26 Jan 24
EFFECT
Notice of effectiveness
11 Aug 23
EFFECT
Notice of effectiveness
6 Jun 23
CORRESP
Correspondence with SEC
31 May 23
CORRESP
Correspondence with SEC
12 May 23
UPLOAD
Letter from SEC
26 Apr 23
CERT
Certification of approval for exchange listing
16 Mar 23
EFFECT
Notice of effectiveness
8 Feb 23
CORRESP
Correspondence with SEC
2 Feb 23
CORRESP
Correspondence with SEC
25 Jan 23